Literature DB >> 12805264

In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides.

Emilia Cercenado, Sonia Cercenado, Juan A Gómez, Emilio Bouza.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12805264     DOI： 10.1093/jac/dkg289

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  4 in total

1.  Meningitis due to vancomycin-resistant Enterococcus faecium successfully treated with combined intravenous and intraventricular chloramphenicol.

Authors:  Pablo Gustavo Scapellato; Cecilia Ormazabal; José Luis Scapellato; Edgardo Gabriel Bottaro
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

Review 2.  Multidrug-resistant Gram-negative infections: what are the treatment options?

Authors:  Helen Giamarellou; Garyphallia Poulakou
Journal:  Drugs       Date:  2009-10-01       Impact factor: 9.546

Review 3.  Antibiotics for treatment of resistant gram-positive coccal infections.

Authors:  Hossam Al-Tatari; Nahed Abdel-Haq; Pimpanada Chearskul; Basim Asmar
Journal:  Indian J Pediatr       Date:  2006-04       Impact factor: 5.319

4.  A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744].

Authors:  María E Oliva; Arcot Rekha; Albert Yellin; Jacyr Pasternak; Maria Campos; Gilbert M Rose; Timothy Babinchak; Evelyn J Ellis-Grosse; Evan Loh
Journal:  BMC Infect Dis       Date:  2005-10-19       Impact factor: 3.090
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.